Novartis Targeting India For Natural Drug Ingredients
This article was originally published in PharmAsia News
Executive SummaryIndia is a prime target for Novartis, the Swiss drug maker looking for biodiverse resources from which to produce drugs. The outgoing chairman of Novartis India said the parent company is looking at the seas, rain forests, fungi and micro-organisms that use natural ingredients to protect themselves. Peter Jager said a Novartis project in China is looking at fungi that contain an ingredient that fights cancer, and at a micro-organism in Thailand that grows on an insect. But Jager said India itself has a great potential for bioresources and is part of the Novartis research plan. (Click here for more
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.